Paz RMT

Language: Spanish
References: 18
Page: 1133-1139
PDF size: 142.10 Kb.

ABSTRACT

A patient having no history or evidences of immune disorders, presented chronic meningoencephalitis. This patient was admitted three times with different diagnosis in a 10-month period. The diagnosis of neurocryptococcosis was confirmed by means of studies with India ink stain and mycological culture of cerebrospinal fluid, no other localization of fungus was found. The patient was discharged after the treatment with Amphotericin B and miconazole along with immunological follow-up to 2014; he was recently discharged after 10 years, definitely excluding an acquired immunocompetence.

REFERENCES

1. Georgi A, Schneemann M, Tintelnot K, Calligaris-Maibach RC, Meyer S, Weber R, et al. Cryptococcus gattiimeningoencephalitisin an immunocompetent person 13 monthsafterexposure. Infection. 2009; 37.

2. Da Silva BK, Freire AK, Bentes Ados S, Sampaio I de L, Santos LO, Dos Santos MS, et al. Characterization of clinical isolates of the Cryptococcus neoformans- Cryptococcus gattii species complex from the Amazonas State in Brazil. Rev Iberoam Micol. 2012; 29(1).

3. Gutierrez EL, Valqui W, Vilchez L, Evangelista L, Crispin S, Tello M, et al. Cryptococcus gattii meningoencephalitis in an HIV-negativepatient from the Peruvian Andes. Rev Soc Bras Med Trop. 2010; 43(4).

4. Hagen F, Boekhout T. The Search for the Natural Habitat of Cryptococcus gattii. Mycopathologia. 2010; 170.

5. Botero J, Ruiz J, Márquez S. Criptococosis en un paciente inmunocompetente. Informe de um caso. Revista CES MEDICINA. 2003 Ene-Jul; 17(1).

6. Escandón P, de Bedout C, Lizarazu J, Agudelo CI, Tobón A, Bello S, et al. Cryptococcosis in Colombia: Results of the national surveillance program for the years 2006-2010. Biomédica. 2012 Jul/Sept; 32(3).

7. Harris J, Lockhart S, Chiller T. Cryptococcus gattii: where do we go from here?. Med Mycol. 2012 Feb; 50(2):113-29.

8. Bava A, Zuliani M. Desarrollo de Cryptococcus neoformans en medios de cultivo empleados para diagnostico bacteriologico. Acta Bioquim Clin Latinoam. 2009; 43(2).

9. Springer DJ, Phadke S, Billmyre B, Heitman J. Cryptococcus gattii, no longer an accidental pathogen?. Curr Fangal Infect Rep. 2012 Dec; 6(4). Revista de Ciencias Médicas de Pinar del Río. 2014; 18(6): 1133-1139

10. Da Silva A, Goldani LZ. Neuroimaging Features of Immune Reconstitution Inflammatory Syndrome in a Patient with AIDS Successfully Treated for Neurocryptococcosis. Case Rep Radiol. 2013; 2013.

11. Zaragoza O, Cuesta I, Rodríguez Tudela JL, Cuenca Estrella M, Buitrago MJ. High-Resolution Melting Analysis for Identification of the CryptocGagooccus neoformans-Cryptococcus gattii Complex. J Clin Microbiol. 2011 Oct; 49(10).

12. Rocha KC, Pinhal C, Cavalcanti S, Vidal M, Toscano M, Moraes Vasconcelos D, et al. Lymphocyte transformation assay for C neoformans antigen is not reliable for detecting cellular impairment in patients with Neurocryptococcosis. BMC Infect Dis. 2012; 12.

13. Sorrell TC, Chen S. Recent advances in management of cryptococcal meningitis: commentary. F1000 Med Rep. 2010; 2.

14. Illnait Zaragozí MT, Martínez Machín GF, Fernández Andreu CM, Hagen F, Boekhout T, Klaassen CH, et al. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infect Dis. 2010; 10.

15. Ngamskulrungroj P, Chang Y, Roh J, Kwon-Chung KJ. Differences in nitrogen metabolism between Cryptococcus neoformans and C. gattii the two etiologic agents of Cryptococcosis. PLoS ONE. 2012; 7(3).

16. Castañeda E, Lizarazo J. Protocolo de estudio y manejo de los pacientes con criptococosis. Infection. 2012; 16(35).

17. Negroni R, Arechavala A, Maiolo E, Bianchi M, Santiso G, Lehmann E. Problemas clínicos en micología medica: problema número 41. Rev Iberoam Micol. 2011; 28(1).

18. Sloan D, Dlamini S, Paul N, Dedicoat M. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev. 2008; 4.